#1ResMed Corporate & Investor Presentation Updated: April 29, 2021#2Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website (investor.resmed.com). In addition to historical information, this presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on ResMed's current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, tax outlook, and the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations. Forward-looking statements can generally be identified by terminology such as "may", "will", "should", "expects", "intends", "plans", "anticipates", "believes", "estimates", "predicts", "potential", or "continue", or variations of these terms, or the negative of these terms or other comparable terminology. ResMed's expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but actual results could differ materially from those stated or implied by these forward-looking statements. ResMed assumes no obligation to update the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the "Risk Factors" identified in ResMed's quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward-looking statements. 2 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed#3Company Overview & Strategy ResMed#4Who we are / what we do . ● . Listed on NYSE & ASX, ~$30B market cap World-leading digital health company with over 14 million 100% cloud-connectable devices - 15.5+ million patients in AirView monitoring ecosystem - 105+ million patient accounts in out-of-hospital care network Innovative designer and manufacturer of award-winning devices and cloud-based software solutions - Diagnose, treat, and manage sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions Products and solutions designed to improve patient quality of life, reduce impact of chronic disease, and lower healthcare costs • Cloud-based software solutions and devices designed to provide connected care, improving patient outcomes and efficiencies for healthcare providers - Tools that allow fewer people to manage more patients - Empower patients to track own health outcomes 4 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 Med my Air Au 85 1:00 points Excellent resultsex A ResMed#5Why invest? - driving long-term shareholder value Market Dynamics Growth & Innovation Financial Results • Underpenetrated markets in sleep and COPD • Healthcare costs continue to increase • Focus on improving patient outcomes • Value-based technology solutions Global leader in digital health for sleep and respiratory care • Long-term growth opportunities •8,100+ patents and designs •~7-8% of revenue invested in R&D • Historical revenue and profit growth . • Recurring revenue • Operating excellence program • Strong track record of disciplined capital deployment Total Shareholder Return (NYSE shares as of 3/31/2021)" 1-yr 32% 3-yr 104% ☐ 5-yr 261% 5 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed#6ResMed 2025: a patient-centric, digitally-enabled strategy ResMed 250 million lives improved in out-of-hospital healthcare 2025 in 2025! Purpose⚫ Empower people to live happier, healthier, and higher quality lives in the comfort of their home Growth Focus Global health epidemics in sleep apnea, COPD, other major chronic conditions, and SaaS solutions that improve care in out-of-hospital settings Growth Advantage Transform care through innovative solutions and tech-driven integrated care to drive superior outcomes, experiences, and efficiency Growth Foundations High-performing, diverse, and entrepreneurial people Industry-leading innovation and business excellence Digital health technology and scientific leadership 6 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 2 80 80 N 8 PI ResMed#7Our Business: Sleep ResMed#8Sleep business strategy Deliver a world-class patient experience through innovative solutions that lower overall costs for treating sleep apnea patients and improve clinical outcomes • OPTIMIZE EFFICIENCIES FOR PROVIDERS Home medical equipment / home care provider-facing solutions that drive workflow efficiencies Long-term adherence solutions that . improve patient management and meet the needs of referring physicians DELIVER BEST-IN- CLASS PATIENT EXPERIENCE Patient-facing solutions, from identification to treatment, that streamline the experience and improve long-term adherence EMBRACE AND ENABLE INTEGRATED CARE MODELS Payer-facing solutions that enable population management, backed by our data insights, outcomes research, and market access Collaboration – Operating Excellence – Lean Innovation – High Performance Culture – Talent 8 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed#9What is sleep-disordered breathing? Abnormal respiration during sleep - the cessation of breathing or "sleep suffocation" Most prevalent is obstructive sleep apnea - collapse of the upper airway despite ongoing effort Other types include central sleep apnea - lack of breathing and lack of effort - and mixed apnea Normal airway Partially obstructed airway Obstructed airway Arousal 9 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed#10Sleep apnea is more than 80% undiagnosed... ....and is highly prevalent in other chronic conditions For every 100 U.S. adults... 4 KNOW THEY HAVE SLEEP APNEA12 •E•E•E•E•E 22 DON'T KNOW THEY HAVE IT1.2 1 Peppard PE et al. Am J Epidemiol 2013 2 Young T et al. Sleep 1997 102021 ResMed | Corporate & Investor Presentation - updated 29APR21 Stroke3 72% Type 2 Diabetes4 72% Obesity5 77% Atrial Fibrillation6 74% Heart Failure? 76% Drug-Resistant Hypertension³ 83% 3 Johnson KG and Johnson DC. J Clin Sleep Med 2010 4 Einhorn D et al. Endocr Pract 2007 6 Bitter T et al. Dtsch Arztebl Int. 2009 7 Oldenburg O et al. Eur J Heart Fail 2007 5 O'Keeffe T and Patterson EJ. Obes Surg 2004 8 Logan AG et al. J Hypertens 2001 ResMed#11The global prevalence of sleep apnea is enormous and growing... United States AHI≥5 = 54 M AHI≥15 24 M France AHI≥5 = 24 M AHI≥15 = 12 M Germany AHI≥5 = 26 M AHI≥1514 M China AHI≥5 Brazil AHI≥5 = 49 M AHI≥15 = 25 M =1 Nigeria AHI≥5 = 31 M AHI≥15 = 12 M Benjafield AV et al. Lancet Respir Med 2019 11 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 176 M AHI≥15 = 66 M Pakistan AHI≥5 = 42 M AHI≥15 17 M India AHI≥5 = 52 M AHI≥15 = 29 M AHI ≥ 5 936,360,689 AHI ≥ 15 424,630,028 Russian Federation AHI≥5 = 40 M AHI≥15 = 20 M Japan AHI≥5 = 22 M AHI≥15 9 M ResMed#12Our partnerships will address sleep health as a public health crisis Sleep research joint venture with Verily Develop software solutions to help identify, diagnose, treat, and manage those with OSA • To study the health and financial impacts of untreated sleep apnea - Prove the ROI for treating OSA Identify, engage, enroll Expand the funnel & verily ResMed 12 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 100 600 Jul With Verily, we can unlock richer, more holistic insights about sleep apnea and the value of treating it ResMed#13Transforming the treatment & management of sleep apnea Quiet Compact W AirSense™ 10 AirSense™ 10 AUTOSET FOR HER Comfortable Minimalist Small. Light. Simple. AirCurve™ 10 Ultra Soft Patented memory foam offers unique comfort. AirFit™ F30 AirFit™ N30 AirFit P10 AirTouch™ F20 Full face mask ill face mask Nasal Pillows System Freedom Sleep in any position. AirFit™ F30i AirFit N30 Nasal cradle mask AirFit™ P30i Nasal pillows mask 13 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 AirMini™ RosMed 90 Connected AirTouch™ N20 Nasal mask brightree by ResMed Universal Fit Classic designs that fit nearly every face. AirFit™ F20 AirFit™ N20 Full face mask Nasal mask 85 85 AirView™ Cloud-based patient management system myAir TM Patient engagement program 85 ResMed#14Our Business: Respiratory Care ResMed#15Respiratory care strategy Changing the lives of COPD patients by bringing new solutions for unmet patient needs WIN IN THE CORE . Reach more COPD patients through connected non-invasive ventilation Drive profitable growth in life-support ventilation . INNOVATE AND EXPAND INTO ADJACENCIES Treat patients earlier in COPD disease progression through a connected ecosystem Continue to leverage investments in life support and NIV Better prove connected health value propositions TRANSFORM COPD HEALTHCARE DELIVERY Build intelligent therapy solutions enabled by sensor technologies, data analytics, Al and ML with improved patient/care giver engagement . Create value propositions in longitudinal care, predict exacerbations, and prevent hospitalization Support new business models & tailored products in emerging growth markets Collaboration – Operating Excellence – Lean Innovation – High Performance Culture - Talent 152021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed#16What is chronic obstructive pulmonary disease (COPD)? COPD is a serious lung disease that over time, makes it hard to breathe Causes include: Smoking, vaping, & secondhand smoke Pollution Occupational exposure to noxious gases . A history of childhood infections (could be a catalyst) Genetic inheritance, leading to its onset 16 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 O 000 000 9 O O 0 O 0 O D 9 ResMed#17COPD is a large and growing market + More than 380 million people worldwide are estimated to have COPD 1 - Largely undiagnosed COPD sufferers in high-growth markets. such as China, India, Brazil and E. Europe may be well over 100 million 1 $ Cost to healthcare systems from COPD is enormous: · Europe: €48 billion per year² + - - United States: ~$50 billion per year³ More than 3 million people worldwide die each year due to COPD4 LET'S TALK ABOUT The Long-term Health and Economic Burden of COPD in the United States A recent study publication (Zafari et al. CHEST 2020) modelled the health and economic burden of COPD in the US over 20 years from 2019 to 2038 ${ Direct medical costs attributable to COPD estimated to be $800.90 billion $101.30 billion estimated indirect costs of work absenteeism $337.13 billion $463.77 billion in men in women 315.08 million estimated number of COPD exacerbations 1. Adeloye D et al. J Glob Health 2015 2. ERS White Book. https://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/ 3. NHLBI. Morbidity & Mortality: 2009 Chart Book on Cardiovascular, Lung, and Blood Diseases 4. WHO 2017 https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd) 17 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 9.42 million estimated COPD deaths ResMed#18There is a need for end-to-end solutions for COPD patients Global population of COPD patients: ~380 million¹ Self-management (smoking cessation, diet, exercise) Inhaled Pharmaceuticals for COPD High Flow Therapy and/or Oxygen Ventilation 75% of pop. Stage II Increasing severity of disease COPD progression Stage I 18 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 1. Adeloye D et al. J Glob Health 2015 20% of pop. <1% of pop. Stage III Stage IV ResMed#19We have the full spectrum of solutions for respiratory care Patient Management ResMed ArView Ventilation patients+ Location - Page, Jimmy palalai Look LANK CLO Foujones, jah AHR D0/171954 Devin 150, Back P nem con My pollo Adration From -204-8150 F-435 Pattanaya Pacitate what Sanct Exaunde: 4houre for 2 drys Jople Ji 1:4 hear 00000 0000-000 cheap look Daverts Water Fedor 10-01-COM) AirView™ for Respiratory Bilevel Ventilation A AirCurve 10™ Digital Therapeutics Hura COPD Assessment Test iconshow your CPO by Daily Schedale High-Flow Therapy jonezu AcuCare TM High Flow Nasal Cannula Propeller Non-invasive Ventilation (NIV) Feed Lumis™ Stellar™ Patient Acuity 19 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 Run Namie D KyCother Resilied They t мнах A Lumis ™M HFT Life Support Ventilation Prefere Astral T TM Astral™ with RCM ResMed#20Our Business: Software as a Service (SaaS) ResMed#21Leading provider of cloud-based software for out-of-hospital care providers across multiple settings Loved One/ Caregiver Physician Patients and Residents $$ Payor MatrixCare® MatrixCare by ResMed Skilled Nursing Home Health Hospice Private Duty Senior Living Life Plan Community HEALTHCARE first HEALTHCARE first by ResMed by ResMed brightree by ResMed ResMed 21 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 Brightree HME, Pharmacy and Home Infusion ResMed Sleep and RC Products & Solutions Hospital ResMed#22SaaS portfolio well positioned to improve outcomes and lower costs across out-of-hospital healthcare Better patient experience. Improved clinical outcomes. Lower overall cost of care. Intelligent workflow Privacy • Security Advanced analytics Interoperability . . Single view of the patient across care continuum • Comprehensive interoperability to improve care transitions, coordination, and collaboration • Seamless access to information for patients and those who care for them Data insights and population management to enable better care / better results • Stronger connections between providers, health systems, and payers Connected systems deliver the best outcomes for value-based care 22 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed#23Digital Health Technology ResMed#24Digital health technology is our foundation Purpose: Enable all ResMed businesses to achieve their business objectives by leveraging technology, data, and advanced analytics. Sleep Respiratory Care SaaS 用 ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ Digital Health Technology Technology 22 Advanced Analytics / AI-ML 24 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed#25Our digital health solutions improve outcomes and lower costs TM myAir APPS/DIGITAL THERAPEUTICS DEVICES ResMed Ecosystem Connected Devices and Digital Health Propeller PATIENT/ CONSUMER AirView™ Out-of-Hospital Platform CLINICIAN IDN HME/PAYORS 25 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 brightree by ResMed 1 Patient Outcomes Artificial Intelligence MatrixCare by ResMed Machine Learning HEALTHCARE first by ResMed -0-0- Business Outcomes Operations ResMed#26We transform 8.5+ billion nights of medical data into useful outcomes End-to-end digital health solutions in sleep, respiratory care, and out-of-hospital healthcare ApneaLink Air Type Ill home sleep testing device Testcompl ResMed ApneaLink Air DIAGNOSIS AirView DIAGNOSTICS Air10™ series AirView™ Astral™ with RCM - > 10 Apterse 10 THERAPY AirMini™ ResMed 26 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 90 www AirView™ ActionGroups 12 34 MyAir 01011 Cor: b Ongping alu 05 10 78 Hatake red 11 B 10 brightree. MONITORING & MGMT. PATIENT ENGAGEMENT BILLING & INTEGRATIONS Go Scripts ReSupply Propeller Compele Relevel and Dumenia. Sule ResMed Data Exchange 3rd Party Integrations I ResMed#27Global leader in digital health AirView™ has 15.5+ million patients 1.5+ million diagnostic tests processed in the cloud ~100 API calls per second from integrators >14 million 100% cloud connectable devices worldwide 105+ million accounts in out-of-hospital care network 3+ million patients have signed up for myAir' TM 27 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed#28Recent Quarterly Results ResMed#29Q3 FY21 financial results Diversified revenue by business & by geography OOH SaaS 12% $ in millions, except per share amounts Revenue Non-GAAP gross margin* Non-GAAP operating income* Non-GAAP EPS* * Refer to Non-GAAP reconciliations in the Appendix. 3Q21 $768.8 +0%, (3)% CC 59.6% (1) bps $241.8 +2% $1.30 +1% Masks & Other 40% Europe, Asia, and Other 35% 29 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 OOH SaaS 12% Devices 48% Americas Sleep and Respiratory Care 53% ResMed#30Capital allocation $ in millions 3Q21 Cash and cash equivalents $231 Debt $731 Net debt $500 Free cash flow $170 Unused borrowing capacity $1,530 NOTE: Values may not calculate due to rounding During 3Q21 $56M invested in R&D (7% of revenue) Paid $57M in dividends to shareholders 30 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 Capital Allocation Organic business growth Free cash flow Higher priority Dividends Share buybacks M&A Lower priority ResMed#31Track record of strong financial returns for shareholders $1.8 Revenue ($B) 12% CAGR $3.1 LTM 3Q16 LTM 3Q21 Non-GAAP Operating Income ($M) 17% CAGR $442 $977 LTM 3Q16 LTM 3Q21 Non-GAAP EPS 15% CAGR $5.31 $2.69 LTM 3Q16 LTM 3Q21 Total shareholder return, TSR (NYSE shares as of 3/31/2021): 1-yr 32% | 3-yr 104% | 5-yr 261% NOTE: See reconciliation to GAAP in Appendix 31 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed#32Our vision is to empower people to take control of their health so they can sleep better, breathe better, and live better lives outside the hospital Connected therapy devices Connected medications Masks Software solutions 8円 Services (Resmed 360) 95 H Improve the patient experience + Increase long- + Lower the + term adherence cost of delivery Improve health + outcomes Measurably + improve economic Improve QOL outcomes outcomes Our business aim is to make our device therapies and connected systems indispensable by combining them with intelligent data products#33In the last 12 months, we changed over 121 million lives with our digital health products and cloud-based software solutions AT&T WR 10:23 PM my deep night Wednesday, January 31 ▾ my Air score 85 100 points. That's a great score! You're well on your way to improving your health, 5:58 usage hours 60/70> Adjust mask seal 5.4 events per hour Jo 3 mask on/off Dashboard 300 Mass Coaching 4/5> Our aspiration is to improve 250 million lives in 2025#34Contact Investor Relations Phone: (858) 836-5971 Email: [email protected] Website: investor.resmed.com#35APPENDIX ResMed#36Reconciliation of non-GAAP financial measures The measures "non-GAAP gross profit" and "non-GAAP gross margin" excludes amortization expense from acquired intangibles related to cost of sales and are reconciled below: (Unaudited; $ in thousands, except for per share amounts) 0000 Three Months Ended Nine Months Ended March 31, 2021 March 31, 2020 March 31, 2021 March 31, 2020 Revenue $ 768,767 $ 769,455 $ 2,320,722 Add back: Deferred revenue fair value adjustment (A) $ 2,186,669 2,102 Non-GAAP Revenue $ 768,767 $ 769,455 $ 2,320,722 $ 2,188,771 GAAP Cost of sales $ 321,509 $ Less: Amortization of acquired intangibles (A) (10,924) 319,793 (12,136) Less: Restructuring - cost of sales (A) Non-GAAP cost of sales GAAP gross profit $ 310,585 $ 307,657 $ $ 972,319 (34,066) (5,232) 933,021 $ 918,256 (37,623) $ 880,633 $ 447,258 $ GAAP gross margin 58.2 % 449,662 58.4 % Non-GAAP gross profit Non-GAAP gross margin SA $ 458,182 59.6 % $ 461,798 60.0 % $ 1,348,403 $ 1,268,413 58.1 % 58.0 % $ 1,387,701 $ 1,308,138 59.8 % 59.8 % (A) ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions, restructuring expenses, deferred revenue fair value adjustment, litigation settlement expenses, the (gain) loss on equity investments and the fair value impairment of investment from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed's performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. 36 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed#37Reconciliation of non-GAAP financial measures, cont'd The measure "non-GAAP income from operations" is reconciled with GAAP income from operations below: (Unaudited; $ in thousands, except for per share amounts) 0000 Three Months Ended Nine Months Ended March 31, 2021 March 31, 2020 March 31, 2021 March 31, 2020 GAAP income from operations $ Amortization of acquired intangibles - cost of sales (A) Amortization of acquired intangibles - operating 223,426 10,924 7,445 $ 217,500 12,136 8,272 $ SA 662,040 $ 586,412 34,066 37,623 23,377 21,872 expenses (A) Restructuring - cost of sales (A) 5,232 - Restructuring operating expenses (A) 8,673 Deferred revenue fair value adjustment (A) Litigation settlement expenses (A) Non-GAAP income from operations $ 241,795 $ SA 2,102 (600) 237,908 $ 733,388 $ 647,409 (A) ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions, restructuring expenses, deferred revenue fair value adjustment, litigation settlement expenses, the (gain) loss on equity investments and the fair value impairment of investment from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed's performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. 37 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed#38Reconciliation of non-GAAP financial measures, cont'd The measure "non-GAAP net income" and "non-GAAP diluted earnings per share" are reconciled with GAAP net income and GAAP diluted earnings per share in the table below: (Unaudited; $ in thousands, except for per share amounts) 0000 Three Months Ended Nine Months Ended March 31, 2021 March 31, 2020 March 31, 2021 March 31, 2020 GAAP net income (loss) $ Amortization of acquired intangibles - cost of sales, net (78,481) 8,395 $ 163,137 9,287 $ 279,405 $ 443,839 of tax (A) 26,136 28,765 Amortization of acquired intangibles - operating 5,721 6,330 17,936 16,723 expenses, net of tax (A) Reserve for disputed tax position (A) 254,776 254,776 Restructuring - cost of sales, net of tax (A) 4,663 - Restructuring operating expenses, net of tax (A) 7,730 (Gain) loss on equity investments (A) (8,476) Fair value impairment of investment (A) 9,100 9,100 Deferred revenue fair value adjustment, net of tax (A) 1,610 Litigation settlement expenses, net of tax (A) (528) Non-GAAP net income (A) $ 190,411 $ GAAP diluted shares outstanding Anti-dilutive shares excluded from GAAP Non-GAAP diluted shares outstanding 145,513 858 146,371 187,854 $ 145,680 582,170 $ 499,509 146,394 145,490 145,680 146,394 145,490 GAAP diluted earnings (loss) per share $ Non-GAAP diluted earnings per share (A) $ (0.54) $ 1.30 $ 1.12 1.29 $ $ 1.91 3.98 $ 3.05 $ 3.43 (A) ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions, restructuring expenses, deferred revenue fair value adjustment, litigation settlement expenses, the (gain) loss on equity investments and the fair value impairment of investment from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed's performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. 38 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed#39Our response to COVID-19: Focused on preservation of life Our ResMed Team Work-from-home policy for all employees when job can be performed remotely Specific actions to protect and support employees working in our manufacturing and distribution sites, including: - - - split shifts (A/B/C) increased cleaning, personal hygiene, and safety protocols including temperature checks - personal protective equipment for all staff (PPE) Increased cadence of communications and engagement with employees • 39 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 Our Stakeholders Fair and ethical allocation of products globally supported by an epidemiological model Transitioned manufacturing lines to support production of ventilation products to meet global demand - - Tripled manufacturing of ventilators Scaled up ventilation mask production more than 10x Updated and ongoing clinical information Increased digital health technology and remote patient care services for customers Business Continuity Established key workstreams and a central task force to guide and manage ResMed through the crisis Ongoing communication with suppliers and partners to ensure continuity and identify gaps Active engagement with key government officials and healthcare systems worldwide Ongoing business modeling and scenario planning ● Prudent cash and expense management ResMed#40Striving for excellence in environmental, social, and governance processes Eliminating unnecessary waste We work to eliminate unnecessary waste in all our systems & processes, such as minimizing our use of natural resources. Minimizing pollution Product stewardship We are minimizing pollution, in particular our non-biodegradable waste to landfill. We design and develop products with reduced impact on the environment through their lifecycle. Responsible compliance We fulfill all relevant and applicable compliance obligations in the countries and communities that we operate in. Increased awareness and continual improvement We drive internal awareness of environmental impacts and monitor our performance through collaboration with others to make continual improvements வஜ் Recognized by others for leading in this space: #106 on Newsweek's 2021 "America's Most Responsible Companies”, #15 in Healthcare & Life Sciences #105 on WSJ's 2020 "Management Top 250”, #18 in Healthcare / Life Sciences 40 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 WSJ MANAGEMENT AMERICA'S MOST 2021 RESPONSIBLE Newsweek COMPANIES statista TOP 250 ResMed#41Turning big data into actionable information Pioneering innovation and providing clinical evidence that support better patient outcomes and improved business efficiencies for customers AirView™ myAir 85 85 85 121% patient adherence with automated compliance coaching Labor Costs² 159% New Patient 155% Setups³ World's largest study for adherence > 128,000 patients Data based on monthly patient setups and compliance rates of DME customers from February 2014 - March 2015. Historical results for this provider over the stated time Crocker, et al., Abstract CHEST 2016 1234 1. Hwang, et al., AJRCCM 2017 2. Munafo, et al. Sleep Breath 2016 3. 4. 41 © 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 124% patient adherence with patient engagement4 ResMed#42Improving adherence to therapy with patient monitoring and resupply ResAdhere: remote monitoring + mask resupply drive improved adherence In a study of ~100k patients with AirView cloud-connected devices... Probability on Therapy (%) 100 100% 0 Resupply group (AirView + Brightree) Control group (non-resupply) 90 Time to Drop out (days) + brightree AirView™ 84% 66% 360 ...the likelihood of therapy termination decreased by >50% after one year and there was a significant increase in daily PAP usage Benjafield, et al. AJRCCM 2018 (abstract) Note: De-identified data from Brightree and AirView were sent to a third-party independent statistician who provided the anonymized analyses and findings. 42 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed#43Long-term CPAP treatment decreases mortality rates and reduces the risk of comorbidities Recent prospective cohort study from the UK published in ERJ Open Research reconfirms treating OSA with CPAP improves health outcomes 30 year study duration 4,502 diagnosed OSA patients 15 year average follow-up time Those who did not use CPAP were 5.63x more likely to die than a long-term (>5 years) CPAP user The study also reconfirms with new data that untreated OSA leads to a greater risk in developing: Dodds et al. ERJ Open Res 2020 43 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 Myocardial Infarction (heart attack) Type 2 Diabetes Mellitus Ischemic Heart Disease ResMed#44Reducing mortality with PAP therapy U.S. multicenter, population-based cohort study . Study included 392 patients with sleep apnea, with 11 years of follow-up •Positive airway pressure therapy associated with a 62% lower risk of all-cause mortality •Death rate was twice as high for persons who did not receive positive airway pressure therapy - (24.7 vs 12.8 deaths per 1000 person years, p = 0.03) Lisan Q et al. JAMA Otolaryngol Head Neck Surg 2019 44 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 100 Proportion Surviving, % 70- 80 80 90 60 0 Sleep Heart Health Study HR, 0.38 (95% CI, 0.18-0.81) PAP prescribed PAP not prescribed 5 10 15 20 Time, y ResMed#45Demonstrated positive dose-response relationship between increased CPAP usage and lower healthcare costs For every one hour per night increase in PAP usage there was an 8% decrease in inpatient visits and a 4% decrease in overall acute care visits.1 Each Hour 8% 4% PAP Usage 1. Kirsch DB et al. J Clin Sleep Med 2019 * Overall visits" includes inpatient, ED, and observation visits. 45 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 Inpatient Visits Overall Visits* ResMed#46Study demonstrates the effectiveness of CPAP therapy and quality of life improvements for those with mild obstructive sleep apnea MERGE trial: clinical effectiveness of CPAP treatment in patients with mild obstructive sleep apnea Demonstrated improvement in 56. ● CPAP -Standard care Quality of Life (SF-36 vitality scale) Treatment effect 7-5 (95% CI 5-3-9-6); p<0-0001 54- for CPAP patients vs. standard • care • Symptomatic benefits: • Reductions in sleepiness 52 Mean vitality score (95% CI) 46- 48- g Improvements in fatigue and depression Compelling evidence supports the need and benefits of treating mild OSA Combined with recently published global prevalence research, 936M patients worldwide can benefit from PAP treatment 44 42- T 40 Baseline Month 3 Visit Change in SF-36 Vitality Scale in Patients with Mild OSA per AASM 2012 Wimms et al. Lancet Respir Med 2019 46 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 MMERGE Dundee Blackpool Liverpool Cambridge Oxford Taunton Plymouth UK Respiratory Sleep Research Network Newcastle Stevenage London (G&ST) London (RB&HT) ResMed#47Big data analysis drives insights for treatment of central sleep apnea Patients with treatment-emergent central sleep apnea (CSA) are 2x more likely to terminate therapy • Opportunity to rethink conventional therapeutic options Minimize risk of therapy termination through early diagnosis • Regularly monitor patients to support adherence to treatment 100 50 Analysis of ~200k CSA patients 22% increase in adherence CMS adherence on CPAP prior to switching 62.7% CMS adherence after switching to ASV 76.6% Switching from therapy CPAP to ASV improved relative adherence by 22% Patients who switched from CPAP to ASV had fewer apneas and hyponeas during sleep 47 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 AM CHEST Journal ResMed#48Opportunity to shift care from hospital to home . Healthcare costs are on the rise Combining non-invasive ventilation (NIV) with home oxygen therapy (HOT) Reduces hospitalization and mortality by 51% - - Increases time to hospital readmission or death by ~90 days JAMA® The Journal of the American Medical Association Admission-free Survival % 100- 80 60 40 20 20 Admission-free survival by treatment arm over one year Adjusted hazard ratio, 0.49 (0.31-0.77); P=.002 Home Oxygen Plus Home NIV Home Oxygen Alone Combination of HOT with NIV reduced hospital readmissions by 58.3% Combination of therapies provided improved patient quality of life and saved >$50k per quality of life adjusted year 01 0 2 4 6 8 10 12 Time (months) 1 P. Murphy et al., Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation. A Randomized Clinical Trial, JAMA .Published online May 21, 2017. doi: 10.1001/jama.2017.4451. 48 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed#49Digital health solutions for inhaled COPD pharmaceuticals • ResMed has end-to-end digital health solutions for COPD patients across stages I, II, III, IV of the disease Uses sensors with inhalers to track medication usage and provide personal feedback and insights UPSTREAM Establishes ResMed as a leading provider of COPD and asthma patient management solutions Enables digital integration of care through the progression of the disease gsk Customers include: Boehringer Ingelheim ORION NOVARTIS $$ Patients + $$ Increased drug adherence and sales Pharma companies signed represent 90% of long-acting respiratory inhalation drugs Improved clinical trial speed and enhanced time to market 49 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 DOWNSTREAM Health and economic outcomes Payers Anthem PBMs EXPRESS SCRIPTS Propeller Clinical insights and efficiencies Health systems Dignity Health. ($$ Patients + $$ Pharmacies Walgreens Patient Acquisition ResMed#50Propeller has demonstrated compelling clinical outcomes 1) Impact of the Propeller solution tracking inhaler usage and location SABA use over time # per day Symptom free days % Healthcare utilization Events 2.0 1.5 -50% 1.0 0.5 Uncontrolled COPD 0.0 0 Uncontrolled Asthma 15 75 50 50 25 +32% 0 50 100 150 200 0 50 100 150 200 Drives a decrease in medication Adherence % 36 +58% 57 40 Control Intervention Drives an improvement in adherence 50 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 Drives an improvement in QOL QoL: Rescue Inhaler use per day # times used 1.5 1.0 -75% 0.5 0.0 1 180 Drives an improvement in QOL -25% 79 Before 59 After Drives a reduction in healthcare utilization Acute care utilization Events per 100 patient years 13 Pre-enrollment Post-enrollment 12 6 5 365 ED + Hosp. ED 2 0 Hosp. Drives a reduction in healthcare utilization ResMed#51Propeller's digital medicine platform drives reduced healthcare utilization ◉Cleveland Clinic Study Overview: Propeller Cleveland Clinic enrolled people into Propeller as part of their routine clinical care and monitored them for at least one year. Providers monitored drug use and adherence to inhaled controller medications, providing follow-up as needed. Population: COPD patients with ≥1 utilization (Emergency Department ("ED") visit or hospitalization) in prior 12 months. N = 39; mean age: 69 years, 51% male, 69% African American, mean FEV11 predicted: 47.2%, mean CAT: 192 Numbe of Hospitalizations and ED visits per person per year LO + M C Results: 12 months prior p = 0.06 4.7 ± 4.1 12 months during monitoring 3.4 + 2.6 3.4 ± 3.2 2.2 ± 2.3 1. FEV1 = Forced Expiratory Volume in 1 second - the volume of air that can be forcibly blown out in the first second after full inspiration. Values between 80% and 120% are considered normal 2. CAT = COPD Assessment Test - an eight-item questionnaire designed to quantify the impact of COPD symptoms on a patient's health status.. Scored between 0-40, <10 Low, 10-20 Medium, 21-30 High, >30 Very high Alshabani K, et al. Electronic inhaler monitoring and healthcare utilization in chronic obstructive pulmonary disease. J Telemed Telecare. 2019 51 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 All-cause COPD Healthcare Utilization ResMed#52History of successful SaaS acquisitions Company UMB AN Location Date Key Product Halifax, NS Canada Aug 2012 U-Sleep JAYSEC TECHNOLOGIES Status Integrated into AirView Rebranded as GoScripts Knoxville, TN Feb 2015 GoJaysec Denver, CO Jul 2015 Care Touch 360 Rebranded as ResMed ReSupply. CareTouch brightree Lawrenceville, GA Feb 2016 by ResMed Brightree Core Operating as a wholly-owned subsidiary, with an independent brand conduittechnology Girard, PA Jun 2017 Brightree MyForms Integrated into Brightree AllCall Connect Joliet, IL Jul 2017 Brightree LiveCall HEALTHCARE first Springfield, MO Jul 2018 first HOMECARE Software (EHR) by ResMed MatrixCare Bloomington, MN Nov 2018 by ResMed X-care setting EHRs Apacheta ACE Integrated into Brightree Integrated into MatrixCare Operating as a wholly owned subsidiary, with an independent brand Apacheta CORPORATION Mobile Business Solutions Media, PA Dec 2018 (a mobile enterprise application platform) Integrated into Brightree as Brightree Mobile Delivery SNAPWORK A division of Brightree Brentwood, TN Jan 2020 SNAP SNAP+RPM Integrated into Brightree as SNAP within Brightree ReSupply CITUS New York, NY Mar 2021 Citus Collaboration Platform Operating as part of ResMed, with an independent brand HEALTH 52 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 ResMed